Silymarin in the prevention and treatment of liver diseases and primary liver cancer

  • J. F
  • G. L
  • 3

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

In chronic liver diseases caused by oxidative stress (alcoholic and non-alcoholic fatty liver diseases, drug- and chemical-induced hepatic toxicity), the antioxidant medicines such as silymarin can have beneficial effect. Liver cirrhosis, non-alcoholic fatty liver and steatohepatitis are risk factors for hepatocellular carcinoma (HCC). Insulin resistance and oxidative stress are the major pathogenetic mechanisms leading the hepatic cell injury in these patients. The silymarin exerts membrane-stabilizing and antioxidant activity, it promotes hepatocyte regeneration; furthermore it reduces the inflammatory reaction, and inhibits the fibrogenesis in the liver. These results have been established by experimental and clinical trials. According to open studies the long-term administration of silymarin significantly increased survival time of patients with alcohol induced liver cirrhosis. Based on the results of studies using methods of molecular biology, silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Furthermore, it exerts an anti-atherosclerotic effect, and suppresses tumor necrosis factor-alpha-induced protein production and mRNA expression due to adhesion molecules. The chemopreventive effect of silymarin on HCC has been established in several studies using in vitro and in vivo methods; it can exert a beneficial effect on the balance of cell survival and apoptosis by interfering cytokines. In addition to this, anti-inflammatory activity and inhibitory effect of silymarin on the development of metastases have also been detected. In some neoplastic diseases silymarin can be administered as adjuvant therapy as well. 2012 Bentham Science Publishers.

Author-supplied keywords

  • *liver cancer/dt [Drug Therapy]
  • *liver cancer/et [Etiology]
  • *liver cancer/pc [Prevention]
  • *liver disease/pc [Prevention]
  • *silymarin/cm [Drug Comparison]
  • *silymarin/ct [Clinical Trial]
  • *silymarin/dt [Drug Therapy]
  • *silymarin/pd [Pharmacology]
  • Hepatitis C virus
  • adjuvant therapy
  • alanine aminotransferase/ec [Endogenous Compound]
  • alcohol metabolism
  • alpha fetoprotein/ec [Endogenous Compound]
  • angiogenesis
  • antiinflammatory activity
  • antioxidant activity
  • apoptosis
  • article
  • aspartate aminotransferase/ec [Endogenous Compound
  • bladder cancer/dt [Drug Therapy]
  • breast cancer/dt [Drug Therapy]
  • cancer inhibition
  • catalase/ec [Endogenous Compound]
  • cathepsin B/ec [Endogenous Compound]
  • cell proliferation
  • clinical trial (topic)
  • colon cancer/dt [Drug Therapy]
  • cyclooxygenase 2/ec [Endogenous Compound]
  • cytokine production
  • diabetes mellitus
  • gamma glutamyltransferase/ec [Endogenous Compound]
  • garlic
  • gelatinase A/ec [Endogenous Compound]
  • gelatinase B/ec [Endogenous Compound]
  • gene expression
  • glutathione peroxidase/ec [Endogenous Compound]
  • hepatitis B
  • hepatitis C/dm [Disease Management]
  • hepatitis C/dt [Drug Therapy]
  • human
  • hyperlipidemia
  • insulin resistance
  • intercellular adhesion molecule 1/ec [Endogenous C
  • kidney carcinoma/dt [Drug Therapy]
  • legalon 140
  • legalon sil
  • life expectancy
  • lipid composition
  • lipid peroxidation
  • liver cirrhosis/dt [Drug Therapy]
  • liver protection
  • liver transplantation
  • low density lipoprotein receptor/ec [Endogenous Co
  • lung cancer/dt [Drug Therapy]
  • malonaldehyde/ec [Endogenous Compound]
  • nonalcoholic fatty liver/dt [Drug Therapy]
  • nonalcoholic fatty liver/et [Etiology]
  • nonhuman
  • obesity
  • oxidative stress
  • peginterferon/cb [Drug Combination]
  • peginterferon/cm [Drug Comparison]
  • peginterferon/dt [Drug Therapy]
  • peroxisome proliferator activated receptor alpha/e
  • prostate cancer/dt [Drug Therapy]
  • quality of life
  • ribavirin/cb [Drug Combination]
  • ribavirin/cm [Drug Comparison]
  • ribavirin/dt [Drug Therapy]
  • risk factor
  • skin cancer/dt [Drug Therapy]
  • stefin A/ec [Endogenous Compound]
  • stomach cancer/dt [Drug Therapy]
  • superoxide dismutase/ec [Endogenous Compound]
  • survivin/ec [Endogenous Compound]
  • tumor necrosis factor alpha/ec [Endogenous Compoun
  • unclassified drug
  • upregulation
  • urokinase/ec [Endogenous Compound]
  • virus inhibition
  • virus load
  • weight reduction

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Feher J.

  • Lengyel G.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free